参考资料: [1] Oxford University/AstraZeneca vaccine authorised by UK medicines regulator. Retrieved December 30, 2020, from网页链接 [2] AZD1222 Oxford Phase III trials interim analysis results published in The Lancet. Retrieved December 30, 2020, from网页链接 [3] AstraZeneca’s COVID-19 vaccine...
Although previous studies have found an association between antibody-binding titers and neutralization with protection across phase 3 COVID-19 vaccine trials15,48, WT S IgG titers and neutralization were not different across vaccinees who did or did not develop beta-variant COVID-19 after ChAdOX1 ...
R. et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med. 385, 2348–2360 (2021). Article CAS Google Scholar Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis...
Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: A double-blind, randomized controlled phase 1/2 trialdoi:10.1016/j.ijid.2021.10.030Michiko AsanoHiroshi OkadaYohji ItohHajime HirataJohan VekemansInternational journal of infectious diseases: IJID: official ...
The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. This interim safety and efficacy analysis was based on 32,449 participants accruing 141 sym...
Fig. 1. Outline study design. The study was split into two phases: An embryofetal development phase provided information on potential effects of AZD1222 on female mating behavior, fertility, pregnancy, implantation, and embryofetal morphological development in utero; a separate littering phase included...
Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: “Today, we have published the interim analysis of the Phase III trial and show that this new vaccine has a good safety record and efficacy against the coronavirus. We are ...
1. Clinicaltrials.gov. A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19. [Onli...
In May 2020, AstraZeneca received support of more than $1 billion from BARDA for the development, production and delivery of the vaccine. The Phase III D8110C00001 trial is part of this funding agreement.
19. In a phase II study of ChAdOx1 nCoV-19 in South Africa, in 2000 adults with a median age of 31 years, vaccine efficacy against mild to moderate disease was reduced when the virus recovered after infection was B.1.351 (19 cases in the vaccinated group and 20 in the placebo group)...